Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer

Zhengliang Li, Xiaojing Liu, Nan Luo, Yali Pang, Yubin Hou, and Guoxiang Jiang

Second Department of Radiotherapy, Yantaishan Hospital, Yantai, China; Department of Traditional Chinese Medicine, Yantai Food and Drug Inspection and Testing Center, Yantai, China; Third Department of Oncology, Weifang Hospital of Traditional Chinese Medicine, Weifang, China; Catheter Room, Affiliated Hospital of Weifang Medical University, Weifang, China

ABSTRACT
This study aims to investigate the potential clinical function of long non-coding RNA CERS6-AS1 (lncRNA CERS6-AS1) integrated miR-567 in gastric cancer. The expression of CERS6-AS1 in gastric cancer tissues was detected through RT-qPCR in contrast to the normal tissues. The correlation between the expression of lncRNA CERS6-AS1 and the characteristics of clinical data was analyzed. Kaplan-Meier curve was used to assess the survival analysis, while Cox proportional hazards model multivariate analysis was performed to evaluate the prognostic risk factors of gastric cancer to verify the prognostic possibility of CERS6-AS1. The expression of CERS6-AS1 in different gastric cancer cells was detected, being the development of gastric cancer cells after knockdown CERS6-AS1 studied using CCK-8, Transwell migration, and invasion detection methods. The targeting effect and interaction between CERS6-AS1 and miR-567 through biological analysis and luciferase activity detection. The expression of lncRNA CERS6-AS1 was elevated in gastric cancer tissues and cells. The results of this study demonstrate that the condition of gastric cancer patients was related to the expression of CERS6-AS1, and therefore CERS6-AS1 might be a prognostic factor for the progression of gastric cancer. In addition, the ability of gastric cancer cells to proliferate, migrate and invade could be reduced by knockdown CERS6-AS1. After CERS6-AS1 knockdown, the expression level of miR-567 in gastric cancer tissues decreased, while the expression level of miR-567 increased. In conclusion, lncRNA CERS6-AS1 might promote the progression of gastric cancer and had the potential as a prognostic marker of gastric cancer.

Introduction
Gastric cancer (GC) is one of the most frequent cancers [1–3]. According to a recent study of 2020, gastric cancer has become the fifth most common cancer in the world [4]. Gastric cancer is characterized by a poor prognosis, high mortality, strong recurrence, and complex causes [5,6]. It has been reported several risk factors associated with gastric cancer, including bad eating and an unhealthy lifestyles, family genes, and living environment [7]. Based on current research, surgery is the best option for the treatment of this cancer [8,9]. However, most patients are diagnosed at the late stage of gastric cancer, and the recurrence rate of surgery is high, and the patients’ condition is unstable [10].

Long non-coding RNAs (lncRNAs), a class of RNA that lack protein-coding capacity and more than 200 nucleotides long, have been shown to play an important role in cell growth and differentiation, and many cancers [11,12]. MicroRNAs (miRNAs) are a type of RNA molecule with a length of about 20 nucleotides, which cannot be used for protein coding [13]. LncRNAs can specifically target and bind miRNAs to regulate the progression of cancer [14,15]. In this context, new evidence suggests that lncRNA may affect the progression of gastric cancer. The development of IncRNA-guided prognostic methods for gastric cancer may be established since the overexpression of lncRNA HOTAIR may be used as a biomarker for a poor prognosis of gastric cancer [16]. Zhang et al confirmed that lncRNA MT1JP, as a down-
regulated IncRNA, may regulate the progression of
gastric cancer, suggesting that MT1JP may become a
potential therapeutic target and a prognostic
marker for gastric cancer [17]. In addition, 
through exploring the molecular mechanism, it has been found that IncRNA CERS6-AS1 may
accelerate the proliferation and growth of cells and slow down the progress of cell apoptosis in breast cancer [18]. However, no detailed studies
exist on the mechanism of action of IncRNA
CERS6-AS1 in gastric cancer.

The present study gradually verified the
mechanism of action of CERS6-AS1 through the
analysis and detection of the expression of IncRNA
CERS6-AS1 and miR-567 in gastric cancer tissues and cells and the clinical relationship. On the other side, the possibility of IncRNA CERS6-AS1
 targeting miR-567 on the growth and prognosis of
gastric cancer cells was determined by knockdown
CERS6-AS1 and the study of interaction between
CERS6-AS1 and miR-567.

### Materials and methods

#### Characteristics of the patients

Patients with gastric cancer (N = 126) were ran-
domly selected and divided into high expression
group (n = 66) and low expression group (n = 60)
according to the mean expression of IncRNA
CERS6-AS1. Table 1 listed the details of the clinical
data of all the included patients. This research
selected patients with gastric cancer diagnosed and
treated by the Seventh People’s Hospital of
Shanghai University of TCM from February 2014
to November 2016. All the included patients
signed an informed consent form under the super-
vision of the ethics committee, ensuring that no
treatments that would affect the results of the
research were taken in advance.

#### Cell culture and transfection assay

Gastric cancer cells BGC-823, AGS, HGC-27, and
SGC-7901 and control cells GES-1 were purchased
from the Institute of Biochemistry and Cell
Biology, Chinese Academy of Sciences (Shanghai,
China). All experimental cells were cultured in
Dulbecco’s Modified Eagle’s medium (DMEM;
Invitrogen, USA) including 10% fetal bovine
serum (FBS; USA), which were incubated in a
37°C cell incubator (DRH-A100, Shanghai,
China) under 5% CO2 conditions [19].

Cell transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, USA).
In the beginning, gastric cancer cells were finely
inoculated in 6-well plates for static culture. After
48 hours, the HGC-27 and AGS gastric cancer
cells were successfully transfected to construct the
knockdown test group si-CERS6-AS1 and the con-
trol group si-NC.

#### Reverse transcription-quantitative polymerase
chain reaction (RT-qPCR)

TRIzol (Invitrogen, USA) method was selected to
obtain total RNA. DNase I reagent (Takara, Japan)
was adopted to further purify the extracted RNA.
Primescript Reverse Transcriptase (Takara, Japan)
was used to obtain cDNA that can be RT-qPCR.
SYBR Premix (Takara, Japan) was used to configure
the reaction system for RT-qPCR. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and U6
were defined as internal references. The data

| Indicators          | Cases (n = 126) | Low (n = 60) | High (n = 66) | P   |
|---------------------|----------------|-------------|--------------|-----|
| Age                 |                |             |              |     |
| ≤ 55                | 64             | 29          | 35           | 0.598 |
| > 55                | 62             | 31          | 31           | 0.165 |
| Gender              |                |             |              |     |
| Male                | 76             | 40          | 36           | 0.054 |
| Female              | 50             | 20          | 30           | 0.269 |
| Tumor size(cm)      |                |             |              |     |
| <5                  | 57             | 33          | 25           | 0.149 |
| ≥5                  | 68             | 27          | 41           | <0.001 |
| Local invasion      |                |             |              |     |
| T1, T2              | 67             | 35          | 32           | 0.149 |
| T3, T4              | 59             | 25          | 34           | <0.001 |
| Differentiation     |                |             |              |     |
| Well, Moderate      | 65             | 35          | 30           | 0.054 |
| Poor                | 61             | 25          | 36           |     |
| Lymph node metastasis |              |             |              |     |
| Negative            | 66             | 49          | 17           |     |
| Positive            | 60             | 11          | 49           |     |

Annotation: GC: gastric cancer.
collected was effectively processed and analyzed by the 2−ΔΔCt method. The primers involved were as follows: CERS6-AS1 forward 5′-GCAGCCCGAG CAGAAGT
GA-3′ and reverse 5′-GAGCATAGGAAGCA ACTCTCAG-3′; GAPDH forward 5′-CATCACTGC
CCA
CCCAG-3′ and reverse 5′-ATGCCAGTGA GCTTCCC-3′; U6 forward 5′-CTCCGTTCGGCA GCACA-3′ and reverse, 5′-AACGCTTCACGAA TTGCGT-3′.

**Cell counting Kit-8 and Transwell assay**

The transfected cells were seeded in a 96-well plate with a seeding density of 2 × 10^3 cells/mL, and continued to be cultured in a 37°C incubator. At the specified time point, 10 μL of Cell Counting Kit-8 (CCK-8) reagent (Dojindo Laboratories, Japan) was placed on the plates [20]. After mixing the reagent and the cells thoroughly, the absorbance of each well was detected at the wavelength of 450 nm, and the average value taken.

The cell migration operation was to add DMEM medium to the upper part of Transwell (Corning, China) and DMEM/F12 medium to the lower part [21]. After 48 hours of co-cultivation, the cells were washed twice with phosphate buffered saline (PBS), and then fixed with glutaraldehyde at 4°C. The cells were stained with crystal violet for 30 min before the observation in the microscope. The operation of the invasion assay is the same as the above-mentioned method, but Matrigel (Becton Dickinson, USA) was added to the upper part of the Transwell before the assay.

**Luciferase activity detection**

The pmirGLO vector (Promega, Shanghai, China) was used to construct WT-CERS6-AS1 (wild-type) and MUT-CERS6-AS1 (mutated-type). Lipofectamine 2000 (Invitrogen, USA) was used to co-transfect HGC-27 cells with WT-CERS6-AS1 or MUT-CERS6-AS1 and miR-567 mimic, mimic NC, miR-567 inhibitor, inhibitor NC, or control. After 48 hours, the dual-luciferase reporter gene detection system (Program, USA) was selected to measure the luciferase activity.

**Statistical analysis**

SPSS 20.0 version (IBM, USA) was performed for data collation and analysis, being the results were expressed as mean ± standard deviation (SD). The χ² test was used to show the relevant clinical data of patients with gastric cancer. The Kaplan-Meier curve was used to assess the survival analysis. Cox proportional hazards model multivariate analysis was used to evaluate the prognostic risk factors of gastric cancer, aiming to study the potential use of CERS6-AS1 as a prognostic biomarker for gastric cancer.

**Results**

The expression level of CERS6-AS1 in gastric cancer tissues and cells was detected by RT-qPCR, aiming to explore the potential of CERS6-AS1 as a prognostic biomarker for gastric cancer. Kaplan-Meier curve and Cox analysis were conducted to evaluate the prognostic value of CERS6-AS1. The functional assays, including CCK-8 assay and Transwell assays, were chosen to investigate the functional role of CERS6-AS1 in gastric cancer, and the dual-luciferase reporter gene assay confirmed the function of gastric cancer and the targeting effect of CERS6-AS1 on miR-567.

**Expression of IncRNA CERS6-AS1 in gastric cancer tissue**

The RT-qPCR method is often chosen to detect gene expression levels. The expression of CERS6-AS1 in gastric cancer tissues and normal tissues is shown in Figure 1. From Figure 1 it can be visualized that the expression of CERS6-AS1 in gastric cancer tissues was markedly higher in comparison with normal tissues, with an increase of about 70%.

Through the analysis of the clinical characteristics of 126 gastric cancer patients, it can be concluded that the expression of CERS6-AS1 is not only related to lymph node metastasis, but also has a significant correlation with tumor-node-metastasis (TNM) stage (P < 0.001). C20 Dec 2021ontrastingly, patient age, gender, gastric cancer tumor size, local invasion, and differentiation
Figure 1. The relative expression of lncRNA CERS6-AS1 in gastric cancer tissues was increased compared with normal tissues by RT-qPCR. ***p < 0.001.

Table 2. Multivariate Cox analysis of clinical characteristics in relation to overall survival.

| Indicators                        | HR     | 95% CI       | P     |
|-----------------------------------|--------|--------------|-------|
| lncRNA CERS6-AS1                  | 4.828  | 2.416–9.648  | <0.001|
| Age                               | 1.056  | 0.605–1.843  | 0.847 |
| Gender                            | 1.200  | 0.688–2.093  | 0.521 |
| Tumor size                        | 1.545  | 0.901–2.651  | 0.114 |
| Local invasion                    | 1.252  | 0.718–2.181  | 0.428 |
| Differentiation                   | 1.269  | 0.729–2.208  | 0.399 |
| Lymph node metastasis             | 2.104  | 1.094–4.044  | 0.026 |
| TNM stage                         | 2.053  | 1.119–3.768  | 0.020 |

Survival analysis of gastric cancer

Kaplan-Meier curve was used to assess the survival status of patients. Figure 2 shows that the survival probability with low expression of CERS6-AS1 (n = 60) and high expression of CERS6-AS1 (n = 66) in 60 months was analyzed. The group with a low expression of CERS6-AS1 had better survival and greater survival probability, while the group with a high expression of CERS6-AS1 had the opposite results (log rank P = 0.001).

The prognostic factors of gastric cancer were determined by multivariate Cox analysis of clinical features and overall survival, and the prognostic possibility of CERS6-AS1 was verified. As shown in Table 2, lncRNA CERS6-AS1 (P < 0.001), lymph node metastasis (P = 0.026) and TNM stage (P = 0.020) are all factors that affect the survival status of gastric cancer patients. Moreover, Cox analysis proved that lncRNA CERS6-AS1 may be used as a prognostic biomarker for gastric cancer.

Research assay of CERS6-AS1 in gastric cancer cells

The expression of CERS6-AS1 was detected in selected gastric cancer cells BGC-823, AGS, HGC-27, SGC-7901, and normal cells GES-1. According to Figure 3(a), the results proved that the expression of CERS6-AS1 determined by RT-qPCR was up-regulated in four gastric cancer cells. The gastric cancer cells HGC-27 and AGS with the relatively highest expression of CERS6-AS1 were selected for follow-up experiments. Figure 3(b) shows that knockdown CERS6-AS1 (si-CERS6-AS1) markedly decreased compared with si-NC and the control group. The results of the research on the proliferation ability of HGC-27 and AGS cells are shown in Figures 3c and 3d. Detecting the optical density (OD) value of knockdown CERS6-AS1 at the
Figure 3. Expression level of IncRNA CERS6-AS1 in different gastric cancer cell lines and analysis of transfection, proliferation, migration and invasion in gastric cancer cells HGC-27 and AGS. (a) The relative expression level of CERS6-AS1 is upregulated in different gastric cancer cells, compared with normal cells GES-1. (b) The relative expression level of CERS6-AS1 in HGC-27, and AGS cells transfected with si-CERS6-AS1 was significantly downregulated. (c) and (d) Proliferative capacity of HGC-27 and AGS cells were reduced that measured by CCK-8. (e) The Transwell assay showed that the migration ability of HGC-27, and AGS cells was downregulated. (f) The Transwell assay showed that the invasion level of HGC-27, and AGS cells was reduced. ***p < 0.001.

wavelength of 450 nm by CCK-8 shows that the proliferation ability of gastric cancer cells was down-regulated. Figure 3(e) shows the measurement results of migration ability it can be seen that the number of si-CERS6-AS1 cells was lower than that of the control groups, indicating that the migration ability of cancer cells will decrease with the knockdown of CERS6-AS1. In the same way, the Transwell method was used to detect the invasion ability of gastric cancer cells, and the results were in agreement, as shown in Figure 3(f).

Determination of luciferase activity and the interaction between CERS6-AS1 and miR-567

In this study, pmirGLO was selected as the vector to construct WT-CERS6-AS1 and MUT-CERS6-AS1. The binding sites of WT-CERS6-AS1 and miR-567 are shown in Figure 4(a), which were obtained by bioinformatics analysis. Through the detection of luciferase activity, it can be found from Figure 4(b) that in wild-type WT-CERS6-AS1, the expression of miR-567 (miR-567 mimic) increases the luciferase activity, while the expression of miR-567 (miR-567 inhibitor) inhibits the increase of luciferase activity. The difference is explained since the mutant MUT-CERS6-AS1 is not affected by the expression level of miR-567 in HGC-27 cells. The expression of miR-567 was detected in gastric cancer tissues. As shown in Figure 4(c), the expression of miR-567 in cancer tissues decreased in comparison with normal tissues. Further study on the interaction between CERS6-AS1 and miR-567, Figure 4(d) shows that CERS6-AS1 and miR-567 are negatively correlated. Thus, as the content of CERS6-AS1 increases, miR-567 gradually decreases. Figure 4(e) shows that in gastric cancer cell HGC-27, the relative expression of miR-567 in si-CERS6-AS1
was significantly increased. Therefore, the knockdown of CERS6-AS1 should promote the expression of miR-567.

The relationship between CERS6-AS1 and miR-567 was further verified by knockdown of CERS6-AS1 recovery assay. HGC-27 cells were cotransfected with control, si-NC, si-CERS6-AS1, si-CERS6-AS1+ miR inhibitor NC or si-CERS6-AS1 + miR-567 inhibitor via Lipofectamine 2000. RT-qPCR results in Figure 5(a) shows that i-CERS6-AS1+ miR-567 inhibitor reversed the promotion of miR-567 expression by knockdown CERS6-AS1. The proliferation of HGC-27 cells was detected by CCK-8 method, and the results are shown in Figure 5(b). Cell proliferation level was downregulated by knockdown CERS6-AS1, but the down-regulated expression was offset after co-transfection of miR-567 inhibitor, and the cells proliferated significantly. Figures 5c and 5d clarify that decreased migration and invasion ability of HGC-27 cells was reversed after the participation of si-CERS6-AS1+ miR-567 inhibitor, and cell viability was enhanced.

**Discussion**

Gastric cancer is a malignant tumor that originates from the epithelium of the gastric mucosa, and its incidence varied according to the regions [22,23]. Studies have shown that the prevalence in males is higher than in females [24–26]. In our country, the early gastric cancer symptoms are not obvious, and the symptoms often show nonspecific features, resulting in a low diagnosis rate. With the development and progress of society, people’s irregular eating and life behaviors contribute to the earlier gastric cancer appearance [27]. Therefore, paying attention to the early diagnosis, treatment, and prognosis of gastric cancer is of great significance to the development of human health.

In the current study, RT-qPCR was used to detect the expression of CERS6-AS1, being found that the content of CERS6-AS1 in gastric cancer tissues increased and showed high expression, and the same was true in gastric cancer cells. In the study of breast cancer by Yan et al, it was found that CERS6-AS1 may improve the proliferation of breast cancer through miR-125a-5p, and the
expression of CERS6-AS1 is up-regulated in breast cancer tissues [28]. Subsequently, CERS6-AS1 was also confirmed to show high expression levels in different pancreatic cancer cell lines [25]. According to the clinical characteristics of gastric cancer patients and Cox analysis, it can be inferred that lncRNA CERS6-AS1 may be a prognostic factor of gastric cancer. Studies have shown that lncRNA can be used for gastric cancer research. For example, lncRNA MAGI2-AS3 was previously proven to be an independent prognostic factor for the survival of gastric cancer patients [29]. The latest research also stated that lncRNA HCP5 may be a new and promising target for the treatment of gastric cancer [30]. Additionally, this study conducted a Kaplan-Meier curve analysis on the survival status of gastric cancer patients. After a 60-month follow-up survey, it can be seen that when CERS6-AS1 expression is low and the probability of survival is higher. Similarly, in the study of Bao et al the Kaplan-Meier survival curve also described the relationship between CERS6-AS1 expression and survival time in breast cancer patients [18]. Yun et al also studied the correlation between the expression of CERS6-AS1 and the overall survival of patients with pancreatic ductal adenocarcinoma [31].

It has been reported that knockdown of LINC00265 could inhibit the proliferation of gastric cancer cells in vitro [32]. Another study found that the high expression of LINC00511 could promote the proliferation and migration of gastric cancer cells [33]. After evaluating the related expression of CERS6-AS1 in gastric cancer tissues in this study, the effects of CERS6-AS1 deletion on cell proliferation, migration, and invasion were identified. Evidence shows that deletion of CERS6-AS1 can also inhibit the
proliferation ability, migration level, and invasion ability of gastric cancer cells. Thus, when CERS6-AS1 is low expressed, the progression of gastric cancer is inhibited and the survival possibility is improved, which is consistent with the results of previous studies on the survival status of patients. Experiments have also shown that knockdown LIFR-AS1 inhibited gastric cancer cell proliferation capacity, invasion level, and migration ability, and induced gastric cancer cell apoptosis [34]. Finally, through biological analysis, such as luciferase activity detection, it was demonstrated that miR-567 was negatively adjusted by lncRNA CERS6-AS1. When the level of CERS6-AS1 decreased, the expression of miR-567 was up-regulated. Similarly, the study of Xu et al about the mechanism of CERS6-AS1 on pancreatic cancer concluded that CERS6-AS1 also negatively adjusted miR-217 [25]. The literature shows that lncRNA CERS6-AS1 is used in the research and analysis of a variety of cancer processes, such as hepatocellular carcinoma [35], pancreatic cancer [25,36], breast cancer [28], and most of them are related to the poor prognosis of tumors by targeting miRNAs. In other words, CERS6-AS1 has been verified herein to play a role in the gene regulation of miR-567, and might be used as a potential biomarker for prognosis assessment.

Conclusion

In conclusion, the results demonstrated in this study clarified that the lncRNA CERS6-AS1 knockdown inhibited the proliferation and growth of cancer cells and other biological functions, while CERS6-AS1 negatively regulates miR-567 to affect the progress of cancer. Thus, lncRNA CERS6-AS1 has the potential to play a prognostic role in promoting the progression of gastric cancer.

Highlights

1. The tissues and cells CERS6-AS1 in gastric cancer was upregulated.
2. CERS6-AS1 might be a promising prognostic biomarker of gastric cancer.
3. Knockdown of CERS6-AS1 could repress the progression of gastric cancer through miR-567 regulation.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Acknowledgments

We are grateful to Seventh People’s Hospital of Shanghai University of TCM for their contribution to providing samples.

ORCID

Yubin Hou http://orcid.org/0000-0003-4514-0579

Data availability statement

The corresponding author can provide relevant data for this study.

References

[1] Feng L, Li J, Li F, et al. Long noncoding RNA VCAN-AS1 contributes to the progression of gastric cancer via regulating p53 expression. J Cell Physiol. 2020;235(5): pp. 4388–4398.
[2] Compare D, Nardone O, Nardone G. Non-steroidal anti-inflammatory drugs in the carcinogenesis of the gastrointestinal tract. Pharmaceuticals (Basel). 2010;3 (8): pp. 2495–2516.
[3] Zhang Y, Xu J, Fu H, et al. UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN1 in gastric cancer. Carcinogenesis. 2021;42(2): pp. 285–293.
[4] Johnston FM, Beckman M. Updates on management of gastric cancer. Curr Oncol Rep. 2019;21(8): p. 67.
[5] Liu X, Ru J, Zhang J, et al. miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS One. 2013;8(6): p. e64707.
[6] Guo X, Liang X, Wang Y, et al. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of advanced gastric cancer. Front Genet. 2021;12: p. 642608.
[7] Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3): pp. 230–236.
[8] Cháirez-Ramírez MH, Moreno-Jiménez MR, González-Laredo RF, et al. Lupane-type triterpenes and their anti-cancer activities against most common malignant tumors: a review. EXCLI journal. 2016;15: pp. 758–771.
[9] Jingyue S, Xiao W, Juanmin Z, et al. TFAP2E methylation promotes 5-fluourouracil resistance via exosomal miR-106a-5p and miR-421 in gastric cancer MGC-803 cells. Mol Med Rep. 2019;20(1): pp. 323–331.
Martella B, Cardin F, Lorenzetti R, et al. Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. BMC Surg. 2012;12(Suppl 1): p. S28.

Lv Z, Xu Q, Sun L, et al. Four novel polymorphisms in long non-coding RNA HOTTIP are associated with the risk and prognosis of colorectal cancer. Biosci Rep. 2019;39(2):BSR20180573.

Wang T, Cao L, Dong X, et al. LINC01116 promotes tumor proliferation and neutrophil recruitment via DDX5-mediated regulation of IL-1β in glioma cell. Cell Death Dis. 2020;11(5): p. 302.

Wang J, Ding Y, Wu Y, et al. Identification of the complex regulatory relationships related to gastric cancer from lncRNA-miRNA-mRNA network. J Cell Biochem. 2020;121(1): pp. 876–887.

Xiao Z, Chen, S, Fang, S, et al. Function and mechanisms of microRNA-20a in colorectal cancer. Exp Ther Med. 2020;19(3): pp. 1605–1616.

Chang ZW, Jia, YX, Zhang, WJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res. 2018;37(1): p. 56.

Liu XH, Sun, M, Nie, FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13(1): p. 92.

Zhang G, Li S, Lu J, et al. LncRNA MT1P1 functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018;17(1): p. 87.

Bao G, Huang J, Pan W, et al. Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA. Cancer Med. 2020;9(1): pp. 278–289.

Duan F, Jia D, Zhao J, et al. Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer. Oncotarget. 2016;7(25): pp. 38427–38439.

Shi X, You X, Zeng W-C, et al. LncRNA PAPAS aggravates the progression of gastric cancer through regulating miRNA-188-5p. Eur Rev Med Pharmacol Sci. 2021;25(6): p. 2462.

Zhang X, Tan Z, Kang T, et al. Arsenic sulfide induces miR-4665-3p to inhibit gastric cancer cell invasion and migration. Drug Des Devel Ther. 2019;13: pp. 3037–3049.

Zhang X, Qin, Y, Pan, Z, et al. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC7901 Cells. Biomolecules. 2019;9(8) 302.

Zhang Y, Huang, H, Zhang, Y, et al. Combined detection of serum MiR-221-3p and MiR-122-5p expression and prognosis of gastric cancer. J Gastric Cancer. 2019;19(5): pp. 315–328.

Yeni M, Korkut E, Aksungur N, et al. Determination of Pentraxin-3, Interleukin-8 and vascular endothelial growth factor levels in patients with gastric adenocarcinoma. Asian Pac J Cancer Prev. 2021;22(5): pp. 1507–1512.

Xu J, Wang J, He Z, et al. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Cell Death Dis. 2021;12 (7): p. 648.

He Y, Wang Y, Luan F, et al. Chinese and global burdens of gastric cancer from 1990 to 2019. Cancer Med. 2021;10(10): pp. 3461–3473.

Dong X, Liu Y. Expression and significance of miR-24 and miR-101 in patients with advanced gastric cancer. Oncol Lett. 2018;16(5): pp. 5769–5774.

Yan L, Li, K, Feng, Z, et al. LncRNA CERS6-AS1 as ceRNA promote cell proliferation of breast cancer by sponging miR-125a-5p to upregulate BAP1 expression. Mol Carcinog. 2020;59(10): pp. 1199–1208.

Li D, Wang J, Zhang M, et al. LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol Ther Nucleic Acids. 2020;19: pp. 109–123.

Yin D, Lu X. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells. Bioengineered. 2021;12(1): pp. 225–239.

Yun Z, Meng F, Li S, et al. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. Aging (Albany NY). 2021;13(4): pp. 6041–6054.

Yang Z, OuYang X, Zheng L, et al. Long intergenic non-coding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis. Bioengineered. 2021;12(1): pp. 1012–1025.

Cui N, Sun Q, Liu H, et al. Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer. Bioengineered. 2021;12(1): pp. 2915–2927.

Pan H, Ding, Y, Jiang, Y, et al. LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis. Cancer Cell Int. 2021;21(1): p. 7.

Zhang J, Lou W. A Key mRNA-miRNA-lncRNA Competing Endogenous RNA Triple Sub-network Linked to Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol. 2020;10: p. 340.

Shen R, Wang X, Wang S, et al. Long Noncoding RNA CERS6-AS1 Accelerates the Proliferation and Migration of pancreatic cancer cells by sequestering MicroRNA-15a-5p and MicroRNA-6838-5p and modulating HMGA1. Pancreas. 2021;50(4): pp. 617–624.